Recent News

• 08.20.2025 - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
• 08.20.2025 - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
• 08.20.2025 - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
• 08.20.2025 - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
• 08.04.2025 - Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
• 08.04.2025 - Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
• 08.04.2025 - Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
• 08.04.2025 - Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.04.2025 - 8-K Current report
• 08.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2025 - EX-99.1 EX-99.1
• 07.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.22.2025 - 144 Report of proposed sale of securities
• 07.09.2025 - 144 Report of proposed sale of securities